Craniopharyngiomas are rare tumors that arise in the suprasellar region of the brain and are known for their aggressive nature despite their WHO grade I. This is due to the complex neuroanatomy of the sellar/suprasellar region and their proximity to the optic nerve apparatus, hypothalamic–pituitary tract, and other critical neuroanatomical structures. Definitive treatment is based on a multidisciplinary approach and often involves a combination of surgical, radiation, and medical therapy. However, there is high morbidity associated with surgery and RT due to the complex neuroanatomy of this region. Recently, BRAFV600E somatic mutation has been identified in most papillary craniopharyngiomas. This discovery has led to the novel use of RAF pathway inhibitors to treat these tumors. We report the successful use of dabrafenib (BRAF inhibitor) and trametinib (mitogen-activated protein kinase kinase inhibitor) in the neoadjuvant setting followed by definitive stereotactic radiosurgery. We propose an algorithm based on available literature on the integration of targeted therapy in the management of papillary craniopharyngiomas. Our observations, together with prior case reports, advocate the incorporation of targeted therapy for unresectable craniopharyngiomas and reinforce that treatment with dual-targeted therapy is safe and effective.
Submitted June 4, 2020; accepted for publication July 20, 2020.
Disclosures: Dr. Chicoine has disclosed that he has received grant/research support from IMRIS Inc.; the Head for the Cure Foundation; and Mrs. Carol Rossfeld and the Alex and Alice Aboussie Charitable Foundation. Dr. Huang has disclosed that he has received grant/research support from Pfizer. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Disclaimer: The REDCap database is supported by Clinical and Translational Science Award (grant UL1 TR000448), the Siteman Cancer Center, and NCI Cancer Center (grant P30 CA091842).
Correspondence: George Ansstas, MD, Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110. Email: email@example.com
LongGV, FlahertyKT, StroyakovskiyD,
. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol2017;28:1631–1639.
LongGV, FlahertyKT, StroyakovskiyD, . Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017;28:1631–1639.2847567110.1093/annonc/mdx176)| false
JohannsTM, FergusonCJ, GriersonPM,
. Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. J Natl Compr Canc Netw2018;16:4–10.
Smith-CohnM, DavidsonC, ColmanH, . Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol 2019;8:CNS48.10.2217/cns-2019-001831818130)| false
KaravitakiN, BrufaniC, WarnerJT, . Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005;62:397–409.10.1111/j.1365-2265.2005.02231.x15807869)| false
LoAC, HowardAF, NicholA, . Long-term outcomes and complications in patients with craniopharyngioma: the British Columbia Cancer Agency experience. Int J Radiat Oncol Biol Phys 2014;88:1011–1018.2466165310.1016/j.ijrobp.2014.01.019)| false
KildayJP, CaldarelliM, MassimiL,
. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol2017;19:1398–1407.
KildayJP, CaldarelliM, MassimiL, . Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2017;19:1398–1407.10.1093/neuonc/nox056)| false
RaoM, BhattacharjeeM, ShepardS,
. Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget2019;10:6038–6042.
BernsteinA, MrowczynskiOD, GreeneA,
. Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity [published online November 1, 2019]. J Neurosurg, doi: 10.3171/2019.8.JNS19643
BernsteinA, MrowczynskiOD, GreeneA, . Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity [published online November 1, 2019]. J Neurosurg, doi: 10.3171/2019.8.JNS19643)| false
LongGV, StroyakovskiyD, GogasH,
. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet2015;386:444–451.